Literature DB >> 20686371

Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis.

Hee Seung Kim1, Woong Ju, Byung Chul Jee, Yong Beom Kim, Noh Hyun Park, Yong Sang Song, Seung Cheol Kim, Soon-Beom Kang, Jae Weon Kim.   

Abstract

BACKGROUND: The role of systematic lymphadenectomy (SL) remains unclear for improving overall survival (OS) in epithelial ovarian cancer (EOC). To evaluate the role of SL in EOC, we performed a meta-analysis for comparing the efficacy for OS between SL and unsystematic lymphadenectomy (USL).
METHODS: After the extensive literature search between January 1995 and December 2008, we analyzed 9 studies (2 randomized controlled trials [RCTs] and 7 observational studies) with 21,919 patients with EOC who underwent staging laparotomy including SL or USL.
RESULTS: Although SL was a favorable factor for OS compared with USL (hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.68-0.76), the efficacy of SL on increased OS could not be determined in all-stage and early-stage EOC owing to the lack of RCTs and the deviation of weight by large-scale observational studies, whereas SL improved OS in advanced-stage EOC (HR, 0.70; 95% CI, 0.67-0.75). Moreover, SL increased OS in patients with all-stage disease who underwent optimal debulking surgery (HR, 0.84; 95% CI, 0.69-0.99), whereas it could not improve OS statistically in early-stage and advanced-stage diseases. However, SL showed increased OS with marginal significance in advanced-stage EOC patients treated with optimal debulking surgery (HR, 0.82; 95% CI, 0.66-1.02).
CONCLUSIONS: These findings suggest the possibility that SL can improve OS in advanced-stage EOC. However, the efficacy of SL on OS is still unknown because of the lack of RCTs, which requires more relevant studies for investigating the role of SL in EOC.

Entities:  

Mesh:

Year:  2010        PMID: 20686371     DOI: 10.1111/IGC.0b013e3181d6de1d

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  13 in total

1.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

2.  Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer.

Authors:  Cornelia Bachmann; Robert Bachmann; Bernhard Kraemer; Sara Yvonne Brucker; Anette Staebler; Falko Fend; Ralf Rothmund; Diethelm Wallwiener
Journal:  Mol Clin Oncol       Date:  2016-08-05

3.  Nodal status--its impact on prognosis in advanced ovarian cancer.

Authors:  C Bachmann; S Bachmann; T Fehm; A Staebler; S Becker; R Rothmund; C Gardanis; E M Grischke; D Wallwiener; E F Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

4.  The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.

Authors:  Cornelia Bachmann; Sara Y Brucker; Bernhard Kraemer; Ralf Rothmund; Anette Staebler; Falko Fend; Diethelm Wallwiener; Eva-Maria Grischke
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-05       Impact factor: 4.553

Review 5.  Global ovarian cancer health disparities.

Authors:  Ganna Chornokur; Ernest K Amankwah; Joellen M Schildkraut; Catherine M Phelan
Journal:  Gynecol Oncol       Date:  2012-12-22       Impact factor: 5.482

6.  Surgical anatomy of the common iliac veins during para-aortic and pelvic lymphadenectomy for gynecologic cancer.

Authors:  Kazuyoshi Kato; Shinichi Tate; Kyoko Nishikimi; Makio Shozu
Journal:  J Gynecol Oncol       Date:  2014-01-08       Impact factor: 4.401

7.  Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment.

Authors:  Cornelia Bachmann; Robert Bachmann; Falko Fend; Diethelm Wallwiener
Journal:  J Cancer       Date:  2016-11-09       Impact factor: 4.207

8.  A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer.

Authors:  Ofer Lavie; David Edelman; Tally Levy; Ami Fishman; Ayala Hubert; Yakir Segev; Eli Raveh; Michal Gilon; Avraham Hochberg
Journal:  Arch Gynecol Obstet       Date:  2017-02-03       Impact factor: 2.344

9.  The value of systematic lymphadenectomy during debulking surgery in the treatment of ovarian cancer: a meta-analysis of randomized controlled trials.

Authors:  Qingqing Lin; Wenchao Liu; Song Xu; Juan Li; Jinyi Tong
Journal:  J Ovarian Res       Date:  2020-05-08       Impact factor: 4.234

10.  Clinical Impact of 18F-FDG PET/CT on the Management of Gynecologic Cancers: One Center Experience.

Authors:  Akram Al-Ibraheem; Abedallatif AlSharif; Ramiz Abu-Hijlih; Imad Jaradat; Asem Mansour
Journal:  Asia Ocean J Nucl Med Biol       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.